CN102099374B - 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 - Google Patents

用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 Download PDF

Info

Publication number
CN102099374B
CN102099374B CN200980125712.3A CN200980125712A CN102099374B CN 102099374 B CN102099374 B CN 102099374B CN 200980125712 A CN200980125712 A CN 200980125712A CN 102099374 B CN102099374 B CN 102099374B
Authority
CN
China
Prior art keywords
alk1
fusion
purposes
polypeptide
seqidno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980125712.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102099374A (zh
Inventor
阿斯亚·格林贝格
约翰·克诺夫
拉温德拉·库马尔
罗伯特·斯科特·皮尔索尔
亚斯比尔·西拉
克里斯蒂安·彼得拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Acceleron Pharma Inc
Original Assignee
Ludwig Institute for Cancer Research Ltd
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Acceleron Pharma Inc filed Critical Ludwig Institute for Cancer Research Ltd
Priority to CN201610297436.0A priority Critical patent/CN105963695A/zh
Publication of CN102099374A publication Critical patent/CN102099374A/zh
Application granted granted Critical
Publication of CN102099374B publication Critical patent/CN102099374B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
CN200980125712.3A 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 Expired - Fee Related CN102099374B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610297436.0A CN105963695A (zh) 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5016808P 2008-05-02 2008-05-02
US61/050,168 2008-05-02
US14413109P 2009-01-12 2009-01-12
US61/144,131 2009-01-12
PCT/US2009/002699 WO2009134428A2 (en) 2008-05-02 2009-05-01 Methods and compositions for modulating angiogenesis and pericyte composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610297436.0A Division CN105963695A (zh) 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Publications (2)

Publication Number Publication Date
CN102099374A CN102099374A (zh) 2011-06-15
CN102099374B true CN102099374B (zh) 2016-06-08

Family

ID=41055305

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980125712.3A Expired - Fee Related CN102099374B (zh) 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
CN201610297436.0A Pending CN105963695A (zh) 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610297436.0A Pending CN105963695A (zh) 2008-05-02 2009-05-01 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Country Status (11)

Country Link
US (4) US8158584B2 (enExample)
EP (2) EP3398966A1 (enExample)
JP (5) JP5719766B2 (enExample)
KR (8) KR20170012595A (enExample)
CN (2) CN102099374B (enExample)
AU (5) AU2009241755B2 (enExample)
BR (1) BRPI0911853A8 (enExample)
CA (1) CA2723449C (enExample)
MX (2) MX391905B (enExample)
TW (3) TWI586364B (enExample)
WO (1) WO2009134428A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12144860B2 (en) 2006-11-02 2024-11-19 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20100090683A (ko) 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
TWI586364B (zh) * 2008-05-02 2017-06-11 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
EP2809335A4 (en) * 2012-02-02 2015-10-28 Acceleron Pharma Inc ALK1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF NIERENZELLENKARZINOMEN
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN105658672A (zh) * 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
BR112017021510A2 (pt) * 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
JP6810702B2 (ja) * 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2018067874A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
WO2019086331A2 (en) * 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
CN114028541A (zh) * 2021-05-21 2022-02-11 中山大学 Gdf2在制备改善肿瘤异常血管的药物中的用途
WO2024153115A1 (zh) * 2023-01-18 2024-07-25 开拓药业(广东)有限公司 抗alk-1抗体及其用途
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2008057461A2 (en) * 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
AU683431B2 (en) 1992-11-17 1997-11-13 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1997007135A2 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ES2169864T3 (es) 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO1999046386A1 (en) 1998-03-13 1999-09-16 Ludwig Institute For Cancer Research ALK-1 RESPONDS TO TGF-β AND SIGNALS THROUGH SMAD-1 AND SMAD-5
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030012792A1 (en) 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
WO2002011785A2 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
CN1685055A (zh) 2001-10-31 2005-10-19 爱尔康公司 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
CA2484994C (en) 2002-04-29 2016-06-14 St. Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
EP1534318A4 (en) 2002-06-27 2009-07-01 Univ Utah Res Found METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS
WO2004039248A2 (en) 2002-10-31 2004-05-13 The General Hospital Corporation Repairing or replacing tissues or organs
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
EP1721257A2 (en) 2004-01-27 2006-11-15 Compugen Ltd. Differential expression of markers in ovarian cancer
US7101618B2 (en) * 2004-05-07 2006-09-05 3M Innovative Properties Company Article comprising fluorochemical surface layer
US7897581B2 (en) 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
DK1933871T3 (da) * 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
US20090170767A1 (en) 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
KR20100090683A (ko) * 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
TWI586364B (zh) * 2008-05-02 2017-06-11 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2008057461A2 (en) * 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells;David Laurent等;《Blood》;20070331;第109卷(第5期);1953-1961 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12144860B2 (en) 2006-11-02 2024-11-19 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof

Also Published As

Publication number Publication date
AU2009241755A1 (en) 2009-11-05
US20090311272A1 (en) 2009-12-17
KR20210113446A (ko) 2021-09-15
JP2019210298A (ja) 2019-12-12
CN102099374A (zh) 2011-06-15
KR20200079567A (ko) 2020-07-03
TWI586364B (zh) 2017-06-11
KR20210014224A (ko) 2021-02-08
AU2018200237A1 (en) 2018-02-01
MX391905B (es) 2025-03-21
KR20110031908A (ko) 2011-03-29
AU2009241755B2 (en) 2015-10-01
AU2018200237B2 (en) 2019-10-03
JP2011520793A (ja) 2011-07-21
JP2015042680A (ja) 2015-03-05
CN105963695A (zh) 2016-09-28
AU2016200018A1 (en) 2016-01-28
AU2021286240A1 (en) 2022-01-06
BRPI0911853A8 (pt) 2018-03-06
TW201737947A (zh) 2017-11-01
MX2010011998A (es) 2011-04-11
US20210388104A1 (en) 2021-12-16
KR20190128254A (ko) 2019-11-15
US8158584B2 (en) 2012-04-17
EP3398966A1 (en) 2018-11-07
KR20170012595A (ko) 2017-02-02
JP2017101068A (ja) 2017-06-08
JP5719766B2 (ja) 2015-05-20
AU2019232838A1 (en) 2019-10-10
BRPI0911853A2 (pt) 2016-06-14
KR20190037355A (ko) 2019-04-05
TWI672151B (zh) 2019-09-21
US20130039910A1 (en) 2013-02-14
JP6194302B2 (ja) 2017-09-06
EP2283040A2 (en) 2011-02-16
KR20180029111A (ko) 2018-03-19
JP2021183652A (ja) 2021-12-02
CA2723449A1 (en) 2009-11-05
AU2019232838B2 (en) 2021-09-16
WO2009134428A3 (en) 2010-03-04
TW200950806A (en) 2009-12-16
CA2723449C (en) 2020-01-21
WO2009134428A2 (en) 2009-11-05
US20180179293A1 (en) 2018-06-28
TW201609138A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
CN102099374B (zh) 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
JP2020150955A (ja) Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CN104321070A (zh) Alk1拮抗剂及其在治疗肾细胞癌中的用途
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
EP2291401A2 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
HK1229690A1 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
HK1229690A (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160608